Aggressive B-cell non-Hodgkin lymphoma
MONDO:0017595Also known as: aggressive B-cell NHL
3003 clinical trials for this condition and its sub-types, 69 tagged with Aggressive B-cell non-Hodgkin lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Aggressive B-cell non-Hodgkin lymphoma
-
Diffuse large B-cell lymphoma 632 trials · 754 incl. sub-types
30 sub-types
- Relapsed/refractory diffuse large B-cell lymphoma 210 trials
- High grade B-cell lymphoma 184 trials
- Primary mediastinal large B-cell lymphoma 175 trials
- T-cell/histiocyte rich large B cell lymphoma 31 trials
- Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly 23 trials
- Diffuse large B-cell lymphoma of the central nervous system 21 trials
- Plasmablastic lymphoma 20 trials
- Primary effusion lymphoma 18 trials
- Diffuse large B-cell lymphoma germinal center B-cell type 13 trials
- Diffuse large B-cell lymphoma activated B-cell type 9 trials
- Lymphomatoid granulomatosis 3 trials · 7 incl. sub-types Sub-types →
- Primary cutaneous diffuse large B-cell lymphoma, Leg type 7 trials
- ALK-positive large B-cell lymphoma 5 trials
- Intravascular large B-cell lymphoma 4 trials
- Diffuse large B-cell lymphoma with chronic inflammation 3 trials
- Primary vitreoretinal large b-cell lymphoma 3 trials
- EZB diffuse large B-cell lymphoma 0 trials · 2 incl. sub-types Sub-types →
- MCD diffuse large B-cell lymphoma 1 trial
- Breast diffuse large B-cell lymphoma 1 trial
- A53 diffuse large B-cell lymphoma 0 trials
- BN2 diffuse large B-cell lymphoma 0 trials
- N1 diffuse large B-cell lymphoma 0 trials
- ST2 diffuse large B-cell lymphoma 0 trials
- Colorectal diffuse large B-cell lymphoma 0 trials
- Gastric diffuse large B-cell lymphoma 0 trials
- Liver diffuse large B-cell lymphoma 0 trials
- Primary pulmonary diffuse large B-cell lymphoma 0 trials
- Small intestinal diffuse large B-cell lymphoma 0 trials
- Splenic diffuse large B-cell lymphoma 0 trials
- Thyroid gland diffuse large B-cell lymphoma 0 trials
-
Mantle cell lymphoma 331 trials
2 sub-types
- Gastric mantle cell lymphoma 0 trials
- Splenic mantle cell lymphoma 0 trials
-
Burkitt lymphoma 220 trials
2 sub-types
- Colon Burkitt lymphoma 0 trials
- Small intestinal Burkitt lymphoma 0 trials
-
Precursor B-cell acute lymphoblastic leukemia 66 trials · 111 incl. sub-types
2 sub-types
- B-cell childhood acute lymphoblastic leukemia 37 trials
- B-cell adult acute lymphocytic leukemia 12 trials
-
B-cell prolymphocytic leukemia 7 trials
Most studied deeper sub-types
-
New pill shows promise for Hard-to-Treat blood cancers in japanese patients
Disease control CompletedThis study tests a drug called acalabrutinib in Japanese adults with advanced B-cell blood cancers (like leukemia and lymphoma). The goal is to see if it is safe and helps control the cancer. Participants take the drug daily, and researchers monitor side effects and how well the …
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
CAR-T therapy takes on standard care in lymphoma battle
Disease control CompletedThis Phase 3 trial tested whether the CAR-T cell therapy tisagenlecleucel works better than standard treatments for adults with aggressive B-cell non-Hodgkin lymphoma that came back or didn't respond to initial therapy. The study enrolled 330 participants and compared how long th…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug combo shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis early-stage study tested two experimental drugs, odronextamab and cemiplimab, in 105 patients with aggressive B-cell lymphoma that had stopped responding to other treatments. The main goal was to check safety and find the best dose. Researchers also looked at how well the dr…
Phase 1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New combo attack on lymphoma shows promise in early trial
Disease control CompletedThis early-phase trial tested a three-part treatment for non-Hodgkin lymphoma: freezing tumors (cryoablation), injecting a personalized dendritic cell vaccine made from the patient's own cells, and giving the immunotherapy drug pembrolizumab (Keytruda). The goal was to find the s…
Phase 1/2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Stem cell transplant study seeks best way to prevent immune attack
Disease control CompletedThis study tested different drug combinations to prevent graft-versus-host disease (GVHD) in 174 people with blood cancers receiving stem cells from an unrelated donor. GVHD is a serious side effect where donor cells attack the patient's body. The goal was to find which drug regi…
Phase 3 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New cocktail targets Hard-to-Treat lymphoma
Disease control CompletedThis study tested a combination of the drug pixantrone plus three other medicines (rituximab, ifosfamide, and etoposide) in 74 adults with a fast-growing type of lymphoma that had returned or not responded to treatment. The goal was to see how many patients had their tumors shrin…
Phase 2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Could a targeted antibody boost chemo for kids with aggressive blood cancer?
Disease control CompletedThis phase 3 trial tested whether adding 6 doses of rituximab to standard chemotherapy improves outcomes for children and teens with advanced B-cell non-Hodgkin lymphoma or B-cell acute leukemia. The study enrolled 482 high-risk patients aged 6 months to 18 years. The goal was to…
Phase 3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug combo shows promise for tough blood cancers in early trial
Disease control CompletedThis early-stage study tested a new drug called PRT2527, alone or with other cancer drugs (zanubrutinib or venetoclax), in 86 people with various blood cancers that had returned or stopped responding to standard treatments. The main goals were to check safety, find the best dose,…
Phase 1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Combination therapy shows promise for Hard-to-Treat lymphoma
Disease control CompletedThis phase II trial tested whether combining the immunotherapy drug pembrolizumab (Keytruda) with targeted radiation therapy could help patients whose non-Hodgkin lymphoma had returned or stopped responding to treatment. Seventeen adults with aggressive lymphoma types received bo…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New shot may shield transplant patients from deadly immune attack
Prevention CompletedThis study tested a drug called abatacept, given as a shot under the skin, to prevent a serious complication called graft-versus-host disease (GVHD) in 29 adults with blood cancers. Participants received a stem cell transplant from a half-matched donor. The goal was to see if aba…
Phase 1/2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
Exosomes: the decoy receptors that may sabotage lymphoma treatment
Knowledge-focused CompletedThis study investigates why some aggressive B-cell lymphomas stop responding to immunotherapy. Researchers are looking at tiny particles called exosomes that are released by tumor cells and may act as decoys, soaking up therapeutic antibodies before they can reach the cancer. By …
Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
Genetic clues could sharpen lymphoma diagnosis
Knowledge-focused CompletedThis study examined genetic changes in 555 patients with aggressive B-cell lymphomas, such as diffuse large B-cell lymphoma. Researchers used a technique called FISH to look for specific gene rearrangements. The goal was to see if these genetic markers could help classify tumors …
Sponsor: Andrés José Maria Ferreri • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:02 UTC